1256375-38-8
Chemical Structure
JGB1741
Synonym(s): ILS-JGB-1741
- CAS No.: 1256375-38-8
- Formula:C27H24N2O2S
- Molecular Weight:440.56
IUPAC Name: (E)-N-benzyl-2-(((2-hydroxynaphthalen-1-yl)methylene)amino)-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxamide
InChIKey: CRTIXRJWHKMWCH-STBIYBPSSA-N
SMILES: OC1=C(C2=C(C=C1)C=CC=C2)/C=N/C3=C(C4=C(S3)CCCC4)C(NCC5=CC=CC=C5)=O
Biological Activity: JGB1741 (ILS-JGB-1741) is a potent and specific SIRT1 activity inhibitor with an IC50 of ∼15 μM. JGB1741 is a weak SIRT2 and SIRT3 inhibitor with an all IC50>100 μM. JGB1741 increases the acetylated p53 levels leading to p53-mediated apoptosis with modulation of Bax/Bcl2 ratio, cytochrome c release and PARP cleavage. JGB1741 has the potential for breast cancer research[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
JGB1741 | 99.37% | JGB1741 (ILS-JGB-1741) is a potent and specific SIRT1 activity inhibitor with an IC50 of ∼15 μM. JGB1741 is a weak SIRT2 and SIRT3 inhibitor with an all IC50>100 μM. JGB1741 increases the acetylated p53 levels leading to p53-mediated apoptosis with modulation of Bax/Bcl2 ratio, cytochrome c release and PARP cleavage. JGB1741 has the potential for breast cancer research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
JGB1741 (Standard) | ≥98% | JGB1741 (Standard) is the analytical standard of JGB1741 (HY-111329). This product is intended for research and analytical applications. JGB1741 (ILS-JGB-1741) is a potent and specific SIRT1 activity inhibitor with an IC50 of ～15 μM. JGB1741 is a weak SIRT2 and SIRT3 inhibitor with an all IC50>100 μM. JGB1741 increases the acetylated p53 levels leading to p53-mediated apoptosis with modulation of Bax/Bcl2 ratio, cytochrome c release and PARP cleavage. JGB1741 has the potential for breast cancer research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
